Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ossianix has announced a strategic investment by H Lundbeck which allows Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders.
Subscribe to our email newsletter
The biopharmaceuticals are produced utilizing Ossianix’s Osss proprietary single domain antibody platform modeled on the shark vNAR structure.
Lundbeck will retain the right to negotiate for certain products and technologies arising from the research at Ossianix.
Ossianix CEO Frank Walsh said that Lundbeck via this investment has chosen to further extend their involvement in the emerging field of biotherapeutics for CNS disorders.
"We also welcome Peter Andersen, senior vice president, external scientific relations to the Board of Directors of Ossianix," Walsh added.